Date,Open,High,Low,Close,Volume,Dividends,Stock Splits,SMA_10,SMA_40,SMA_120,Close_10_%_D,10_40_%_D,40_120_%_D,RSI,earningsGrowth,revenueGrowth,profitMargins,grossMargins,returnOnEquity,debtToEquity,priceToBook,forwardPE,longName,sector,longBusinessSummary
2025-06-18,2.569999933242798,2.5999999046325684,2.569999933242798,2.569999933242798,2951,0.0,0.0,,,,,,,,,-0.778,0.0,0.0,-0.47733003,,0.68603045,,Lärkberget AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-06-19,2.569999933242798,2.569999933242798,2.440000057220459,2.5,25364,0.0,0.0,,,,,,,0.0,,-0.778,0.0,0.0,-0.47733003,,0.68603045,,Lärkberget AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-06-23,2.549999952316284,2.5999999046325684,2.4100000858306885,2.4100000858306885,5606,0.0,0.0,,,,,,,0.0,,-0.778,0.0,0.0,-0.47733003,,0.68603045,,Lärkberget AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-06-24,2.4200000762939453,2.4800000190734863,2.4000000953674316,2.4100000858306885,6648,0.0,0.0,,,,,,,0.0,,-0.778,0.0,0.0,-0.47733003,,0.68603045,,Lärkberget AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-06-25,2.490000009536743,2.490000009536743,2.4100000858306885,2.4700000286102295,8157,0.0,0.0,,,,,,,30.984060071136867,,-0.778,0.0,0.0,-0.47733003,,0.68603045,,Lärkberget AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-06-26,2.4200000762939453,2.4200000762939453,2.3499999046325684,2.369999885559082,8685,0.0,0.0,,,,,,,19.911029315372076,,-0.778,0.0,0.0,-0.47733003,,0.68603045,,Lärkberget AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
2025-06-27,2.4100000858306885,2.5899999141693115,2.4000000953674316,2.4800000190734863,107258,0.0,0.0,,,,,,,43.732288200284245,,-0.778,0.0,0.0,-0.47733003,,0.68603045,,Lärkberget AB (publ),Healthcare,"CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden."
